Scroll down to see more

Laekna Announces Three Presentations at AACR 2024


March 6, 2024 — Laekna (2105.HK) today announced that the company will make three poster presentations at the 2024 Annual Meeting of the American Association for Cancer Research (AACR).  The presentations will feature data of two pre-clinical studies and one clinical trial.


The Annual Meeting of AACR will be held from April 05 to 10, 2024 at the San Diego Convention Center, California, USA. It is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.


Study 1:Clinical Study

Title: Phase l/ll clinical trials of LAE005, afuresertib plus nab-paclitaxel in patients with advanced solid tumors, primarily in patients with triple-negative breast cancer (TNBC)

Session Title: Phase 0 and Phase | Clinical Trials Session

Authors: Binghe Xu, Ying Zhang,Ying Wang, Zhongsheng Tong, Tingjing Yao, Xian Wang, Zijia Wang, Pengfei Guo, Wenyue Ma, Yong Yue

Date and Time: Monday Apr 8,2024 1:30 PM - 5:00 PM (PT)

Location: Poster Section 49

Poster Board Number:7


Study 2:Pre-Clinical Study

Title: Preclinical characterization of LAE119, a novel PARP1 selective inhibitor and trapper

Authors: Ming Li, Yan Chen, Junyan Chen, Ling Jiang, Xiaofen Lin, Justin Gu

Session Category: Experimental and Molecular Therapeutics

Session Title: DNA Damage and Repair

Session Date and Time: Wednesday, Apr 10, 2024 9:00 AM- 12:30 PM (PT)

Location: Poster Section 22

Poster Board Number: 27


Study 3:Pre-Clinical Study

Title: Preclinical candidate LAE120, a novel selective USP1 inhibitor shows effective anticancer and combination activity with PARP inhibitors

Authors: Jintao Wang, Yan Chen, Junyan Chen, Ling Jiang, Xiaofen Lin, Chaojun Cai, Minhua Zhang, Ming Li, Justin Gu

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Antitumor Agents 2

Session Date and Time: Sunday, Apr 7, 2024 1:30 PM- 5:00 PM  (PT)

Location: Poster Section 27

Poster Board Number: 16


About AACR


The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.

The mission of the AACR is to prevent and cure cancer. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The AACR has more than 58,000 members residing in 141 countries and territories.



-  End –


About Laekna


Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer and liver fibrosis patients worldwide.


As of June 30, 2023, Laekna has initiated six clinical trials for afuresertib (LAE002), LAE001 and LAE005 to address unmet medical needs in cancers, such as ovarian cancer, breast cancer and prostate cancer. Among the six clinical trials, three are multi-regional clinical trials (MRCTs), including one pivotal trial.


Laekna’s internal drug discovery platform has discovered 12 drug candidates. LAE102 is our first internally discovered antibody which has obtained IND approvals from the FDA and CDE. Its potential indications include muscle regeneration, obesity, and cancer.


Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023. The stock code is 2105.HK.


For more information, please visit:




Forward Looking Statements



This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions, and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.


Contact us:




Business Development

RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin